About this trial
Treatment for blood cancers has improved significantly, and more patients are now living longer. However, these treatments are often intensive and long-lasting, and many patients experience serious side effects and symptoms. As more patients require ongoing treatment and long-term care, the demand for haematology services is increasing.
Home-based treatment is expected to play an increasingly important role in the future. It can support more patient-centred care, help patients maintain their everyday lives, improve quality of life, and reduce pressure on hospitals. Despite these benefits, some patients are either not eligible for home-based treatment or choose to decline it. The reasons for this are not yet well understood.
This study combines quantitative data-such as medical information, sociodemographic characteristics, and questionnaire responses about quality of life and health literacy-with qualitative interviews involving patients, relatives, and healthcare professionals. The aim is to identify barriers and differences between patients, and to better understand why some patients opt out of or are unable to participate in home-based treatment.
The findings will help support the development of more inclusive and patient-centred care models, ensure more equal access to home-based treatment, and improve support for socially vulnerable patients. The results will be shared with patients and families through patient organisations, with hospitals through the Treat@Home programme, and at national and international conferences.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
>=18 years old
diagnosed Multiple Myeloma or acute leukemia, and recieving treatment with either Daratumumab or Cytarabine.
Disqualifiers
None
Trial population
All patients from the Department of Hematology at Odense University Hospital and Zealand University Hospital who are enrolled in the two Treat@Home studies will be invited to participate, including those who accept, decline, or are deemed ineligible for home-based treatment. We aim to include 50 participants, with 25 recruited from each site.
Trial design
Other
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Perceptions - patient
Semi-structured interviews with patients at inclusion
Perception - caregivers
Semi-structured interviews with caregiver (together with patient) at inclusion
Perception - Healthcare staff
Focus group interview with Healthcare staff at end of study (after inclusion of all patients) in regards to barriers and possibilities in home administration
Secondary outcomes
Biological sex
male, female
Patient reported outcomes
Health literacy was assessed using the Health Literacy Questionnaire (HLQ), which contains multiple domains scored on separate scales, with higher scores indicating better health literacy.
Patient Reported Outcome
Quality of life was assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30; scores range from 0-100, with higher functional and global health scores indicating better quality of life and higher symptom scores indicating greater symptom burden).
Caregiver burden
Caregiver burden was assessed using the Caregiver Roles and Responsibilities Scale (CRRS), with higher scores indicating greater caregiver burden.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: